News

As the debate on hydroxychloroquine rages on, the FDA and a new advocacy group have sparred about the appropriateness of physicians prescribing the drug for COVID-19.

A New York City cardiologist talks about the presentation of patients with severe COVID-19 who experienced this condition.

After review of 2 randomized trials, a panel of health care providers and patients see limited benefit for the medication.

The trial will assess a monoclonal antibody based investigational treatment that may prevent COVID-19.

The VIP antiviral therapy shows capability in reducing COVID-19 inflammatory biomarkers, as well as respiratory failure risks.

Collodial stability measures may predict whether a potential antibody-based treatment will work early on in the drug development process.

Medha Munshi, MD, discusses the specific challenges of the quarantine and how she was able to help her patients with diabetes comply with their care.

Manufacturers announce their supplies are being sent out for the upcoming season.

Since the emergence of the SARS-CoV-2 pandemic in particular, news in the infectious disease drug and medical device pipeline has moved at an accelerated pace.

New findings show "structural inequities" among the US and UK frontline responders first infected months ago.

Dr. Anthony Fauci, CDC's Dr. Robert Redfield, & HHS' Admiral Brett Giroir spoke at a congressional hearing on coordinating the future of the national coronavirus response.

GSK, Sanofi were selected by US Operation Warp Speed to provide a large supply.

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.

What role does new research play in combating public vaccination concerns?

Peter Hotez, MD, PhD, recently authored a paper proposing a federally directed but state-adaptive reopening that aims for acceptable national suppression by October 1.

IDSA, HIVMA request they be included in ongoing COVID-19 clinical trials.

A discussion on the process by which the FDA regulates vaccine candidates at a time when COVID-19 candidates are progressing.

Here is a compilation of the COVID-19 vaccine candidates that have achieved FDA Emergency Use Authorization, other approvals, and are in phases 1-3.

RedHill Biopharma has initiated a global phase 2/3 study in order to evaluate the use of opaganib in patients with severe COVID-19.

On Tuesday, Cain was said to be recovering, possibly reflecting the complex immune system stages of COVID-19 disease course.

Why reducing pandemic research and response to yes-or-no outcomes is harming public health.

MJH Life Sciences is presenting a webinar today on this important topic.

People with travel links to China, Iran, and Italy may have accounted for nearly two-thirds of early COVID-19 cases in affected countries.

The method extracts SARS-CoV-2 RNA with the Mag-Bind Viral RNA Xpress Kit and the Hamilton MagEx STAR.

Dr. Adam Brufsky, an oncologist, compares viral and cancer immunity. Dr. Patrick Soon-Shiong connects the relation to COVID-19 vaccine research.

What should be anticipated in effectiveness and implication for the leading candidates.

Roche’s tocilizumab did not improve clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia.

Infectious disease specialists explain how long term international cooperation with impacted societies can help to stop the cycle of Ebola outbreaks.